Comorbid conditions are a risk for osteonecrosis of the jaw unrelated to antiresorptive therapy

Kenneth E. Fleisher, Malvin N. Janal, Nicole Albstein, James Young, Vanessa Bikhazi, Shlomit Schwalb, Mark Wolff, Robert S. Glickman

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: Osteonecrosis of the jaw (ONJ) is commonly associated with antiresorptive therapy. There have been numerous reports of ONJ unrelated to antiresorptive therapy (ONJuat), confounding risk assessment. This study aimed to determine if ONJuat is associated with one or more particular comorbidities. Study Design: This was a retrospective case-control study of patients with ONJuat and delayed healing (DH). Each case was matched for patient age and gender, as well as location of ONJuat or DH lesion to a control patient who had a history of dentoalveolar surgery with uneventful healing and no history of antiresorptive therapy. Comorbidity data included medical conditions and smoking. Results: Of the 92 patients identified, 67 (73%) met the criteria for ONJuat and 25 (27%) for DH. The most common trigger for ONJ and DH was extraction (50%). The presence of any comorbidity (i.e., at least 1) was more prevalent in ONJuat than among controls (P =.04), and there were more comorbidities in patients with ONJuat and DH than in controls [M(SD) = 1.94 (1.2) and 2.0 (1.3) vs 1.26 (0.89); both P <.001]. Conclusions: ONJ and DH are not limited to patients with a history of antiresorptive therapy. More comorbidities may signal increased risk for ONJuat and DH.

Original languageEnglish (US)
Pages (from-to)140-150
Number of pages11
JournalOral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Volume127
Issue number2
DOIs
StatePublished - Feb 2019

ASJC Scopus subject areas

  • Surgery
  • Oral Surgery
  • Pathology and Forensic Medicine
  • Dentistry (miscellaneous)
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Comorbid conditions are a risk for osteonecrosis of the jaw unrelated to antiresorptive therapy'. Together they form a unique fingerprint.

Cite this